Canna-V-Cell Sciences Inc. announces Israel health ministry approval

Vancouver, British Columbia--(Newsfile Corp. - November 19, 2018) - Canna-V-Cell Sciences Inc. (CSE: CNVC) (the "CannaVcell") CannaVcell, in its aim to develop and produce Cannabis active ingredients on the basis of the biofarming technology, is announcing that it has received through its subsidiary in Israel, the authorization of the health ministry of Israel to conduct research and development with Cannabis plants. "This is a major milestone in the adaptation of the cell growth technology to Cannabis. Our ability to conduct our lab activities directly with the plant allows us to accelerate the program and validate the biofarming technology with Cannabis", said Dr. Yochi Hagay the CTO of CannaVcell. Dr. Zaki Rakib, CEO, added "We are glad to have received such authorization a month ahead of the plan. The team is totally committed to the success of the program which is set to revolutionize the Cannabis industry".

About Canna-V-Cell Sciences Inc.

Based in Vancouver BC, Canna-V-Cell Sciences Inc. (CNVC) is the exclusive Cannabis worldwide licensee of the proprietary and patent protected BioHarvest technology. It is the first and only industrial large scale plant cell growth technology capable of directly and constantly producing the active plant ingredients without the necessity to grow the plant itself. By adopting this technology and building adequate cells production capacity, Canna-V-Cell's objective is to become the leading supplier of Cannabis for both the medicinal and recreational legal use.

Canna-V-Cell Sciences Inc.
Dr. Zaki Rakib
CEO

For further information, please contact:
David Ryan
Phone: (604) 622-1186
Email: Midnight.star.ventures@gmail.com

Forward-Looking Statements Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. The Company cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond the Company's control. Such factors include, among other things, risks and uncertainties relating to the fact that the Company would require additional funds in order to construct a commercial biochamber facility and risks related to the adaption of the BioHarvest technology to cannabis. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.

Neither Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.